Oral Drug Delivery Specialist Co-Sponsors Controlled Release Society’s Young Investigator Award

Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that focuses on developing patient-optimised oral products utilising its proprietary pharmaceutical technologies and development expertise, has announced its co-sponsorship of the Controlled Release Society’s Young Investigator Award. The award will be presented during the 40th Annual Meeting & Exposition of the Controlled Release Society, om July 21–24, 2013 in Honolulu, Hawaii.

Aptalis Pharmaceutical Technologies joins the Controlled Release Society in recognising Ali Khademhosseini, MASc, PhD, Associate Professor of Medicine at Harvard-MIT’s Division of Health Sciences and Technology and Harvard Medical School, Brigham & Women’s Hospital and Associate Faculty, the Wyss Institute, US.

Dr. Khademhosseini is developing micro- and nanoscale technologies to control cellular behaviour for tissue engineering and drug delivery applications. He has published over 220 peer-reviewed papers and 160 abstracts. He has received numerous awards, including the NSF Career, PECASE, ONR Young Investigator, Colburn, Y. C. Fung, IEEE EMBS, and IEEE Nanotechnology. He received his PhD in bioengineering from MIT and master’s and bachelor’s degrees from University of Toronto, US, both in chemical engineering.     

The Young Investigator Award recognises a CRS member who has made outstanding contributions in the science of controlled release and who is 40 years of age or younger in the year the award is presented.

Aptalis Pharmaceutical Technologies, +1 908 927 9600, eobrien@aptalispharma.com, www.aptalispharmatech.com.